title: Normalization of serum p53 antibody levels in patients after curative resection for colorectal cancer.
abstract: BACKGROUND
  The aim of this study was to evaluate the significance of high serum p53 antibody (p53Ab) levels in relation to curative resection of colorectal cancer.
  
  
  METHODS
  Between 2007 and 2010, 24 patients with colorectal cancer with higher-than-normal preoperative serum p53Ab, measured by enzyme-linked immunosorbent assay, were enrolled in this study. After curative resection, their serum p53Ab and carcinoembryonic antigen (CEA) levels were measured at one, six, 12, 18, and 24 months after surgery. The relationship between clinicopathological features and the presence of serum p53Ab was evaluated.
  
  
  RESULTS
  None of the patients developed recurrence up to 24 months after the surgery. The positive rate for CEA was 33.3% before surgery, 16.7% at one month after surgery, and 0% at six months and more, while the rate for p53Ab was 75% at six months, 70.8% at 12 months, 58.3% at 18 months, and 54.2% at 24 months after surgery. The positive rate for serum p53Ab at 24 months after the surgery correlated with the one before and that at one month after the surgery.
  
  
  CONCLUSIONS
  For patients with colorectal cancer and high preoperative serum p53Ab levels, serum p53Ab does not seem to be a useful marker of recurrence after curative resection, since normalization of serum p53Ab levels requires years after surgery.
authors: Department of Surgery, Kashiwa Hospital, Jikei University School of Medicine, 163-1 Kashiwashita, Kashiwashi, Chiba 277-8567, Japan. kawahide@jikei.ac.jp
authors: Hidejiro
authors: H
authors: Kawahara
authors: Kazuhiro
authors: K
authors: Watanabe
authors: Hiroya
authors: H
authors: Enomoto
authors: Yoichi
authors: Y
authors: Toyama
authors: Tadashi
authors: T
authors: Akiba
authors: Katsuhiko
authors: K
authors: Yanaga
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000912:Antibodies, Neoplasm / Q000097:blood*; D014408:Biomarkers, Tumor / Q000097:blood*; D002272:Carcinoembryonic Antigen / Q000097:blood / Q000276:immunology; D015179:Colorectal Neoplasms / Q000097:blood* / Q000276:immunology / Q000473:pathology / Q000601:surgery; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000097:blood* / Q000276:immunology / Q000473:pathology / Q000601:surgery; D009367:Neoplasm Staging; D011379:Prognosis; D016159:Tumor Suppressor Protein p53 / Q000097:blood / Q000276:immunology*
chemical_list: D000912:Antibodies, Neoplasm; D014408:Biomarkers, Tumor; D002272:Carcinoembryonic Antigen; C495901:TP53 protein, human; D016159:Tumor Suppressor Protein p53
keywords: Serum p53 antibody; colorectal cancer; curative resection; recurrence; tumor marker